<DOC>
	<DOCNO>NCT02607059</DOCNO>
	<brief_summary>Epidemiologic retrospective multicenter registry patient diagnose de novo secondary acute myeloid leukemia ( AML ) PETHEMA Group institution . This study non-interventional research regard diagnosis therapeutic approach</brief_summary>
	<brief_title>Epidemiologic Registry PETHEMA LMA 2015</brief_title>
	<detailed_description>To perform registry , every patient diagnose AML participant institution , regardless type AML treatment administer , must report . It require registry main characteristic patient AML diagnosis , cytomorphologic , immunophenotypic , cytogenetic result , accord habitual practice center . The treatment administer every center PETHEMA Group , even consider supportive care , evolution disease also report ( relapse death ) . PETHEMA Group input report information data base</detailed_description>
	<criteria>Patients diagnose acute myeloid leukemia No exclusion criterion</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>